Concord Medical Services Holdings Ltd annual report, Q4 FY2015

Full document

Concord Medical Services Holdings Limited — FY2015 Form 20-F

Reporting period: Fiscal year ended December 31, 2015. The filing is an annual report, not a standalone 2015 Q4 report; it does not provide clear standalone fourth-quarter results. Financial statements are prepared under U.S. GAAP and reported in RMB. U.S. dollar translations use RMB6.4778 per US$1.

Business context

Concord operated 127 cooperative radiotherapy and diagnostic imaging centers in 76 hospitals across 53 Chinese cities, and acquired Concord Cancer Hospital in Singapore in April 2015. Its strategy is shifting toward company-owned specialty cancer hospitals, premium cancer hospitals and proton therapy centers. Network business generated 97% of FY2015 revenue; the Singapore hospital contributed the remaining 3%.

Financial performance and position

  • Revenue: RMB616.5 million (US$95.2 million), up 1.6% from RMB606.9 million. Network revenue fell 1.5% to RMB597.7 million; Singapore hospital revenue was RMB18.7 million.
  • Profitability: Gross profit fell 20.8% to RMB263.1 million and gross margin declined to 42.7% from 54.8%. Operating loss was RMB5.7 million, versus operating income of RMB183.6 million in 2014. Net loss was RMB79.3 million, compared with net income of RMB120.3 million. Basic loss per share was RMB0.58 and loss per ADS was RMB1.75.
  • Cost and operating trends: Cost of revenue rose 28.7% to RMB353.3 million. Operating expenses rose 80.9% to RMB268.9 million, including RMB23.1 million of long-lived asset impairment. Management attributed margin pressure mainly to revised cost-sharing terms with some hospital partners and a gross loss at the Singapore hospital. Treatment cases fell 15.8% and diagnostic cases fell 4.3% from 2014.
  • Unusual items: Results included a RMB33.7 million gain from changes in derivative fair value, a RMB36.6 million debt-extinguishment loss, and RMB33.6 million of other income. Other income included a RMB12.8 million bargain-purchase gain on the Singapore acquisition and a RMB16.4 million gain on disposal of a subsidiary. These items materially affected reported earnings.
  • Cash flow: Operating cash flow was negative RMB175.1 million, versus positive RMB490.4 million in 2014; management cited land-use-right deposits as a major factor. Investing cash outflow was RMB391.1 million, including the Singapore acquisition and capital investment. Financing cash inflow was RMB590.4 million. Cash increased RMB6.8 million to RMB485.4 million.
  • Liquidity and debt: Current assets were RMB1.505 billion and current liabilities RMB1.511 billion, leaving net current liabilities of RMB5.9 million. Restricted cash was RMB555.0 million and short-term investments RMB60.0 million. Bank and other borrowings totaled RMB1.190 billion; separate secured borrowings were RMB417.0 million. The company reported RMB2.2 billion of unused bank credit lines and said cash and expected operating cash flow should cover needs for at least 12 months.
  • Balance sheet: Total assets were RMB3.601 billion, total liabilities RMB2.168 billion and equity RMB1.434 billion. The company declared a US$44.5 million special dividend in December 2015, recorded as payable at year-end.

Changes versus prior year

  • Revenue growth slowed to 1.6% from 7.8% in 2014, while network revenue contracted as 12 cooperative centers closed.
  • Margins and operating results deteriorated sharply as costs rose faster than revenue; the company moved from operating profit and net income to operating and net losses.
  • Operating cash flow turned negative. Borrowings increased, and the company had a small net current liability position at year-end.
  • The Singapore hospital acquisition began contributing revenue in 2015 but generated a reported net loss of RMB39.6 million after acquisition. The company also increased its MD Anderson proton-center investment.

Outlook, risks and contingencies

  • Expansion and funding: Management estimated 2016 capital expenditures of RMB600–800 million, mainly for hospital construction. It estimated RMB570 million for proton and premium hospital projects and RMB150–250 million annually for planned specialty-hospital expansion. Management expected approximately 70% of hospital funding from bank loans and 30% from operating cash flow.
  • Execution risks: New hospitals and proton centers require substantial investment, approvals, construction, qualified staff and patient acceptance. The company acknowledged limited experience operating its own hospitals and proton therapy services; project delays, cost overruns or weak patient volumes could pressure liquidity and profitability.
  • Regulatory and operating risks: Chinese equipment quotas, licensing requirements, regulated pricing and possible challenges to hospital cooperation arrangements could constrain operations or expansion. Five equipment units lacked procurement licenses or permits; the related centers generated approximately 3.0% of 2015 revenue.
  • Concentration and collections: The five largest hospital partners accounted for 25.3% of revenue, and the top ten partners represented 42.5% of network receivables. Average network receivable turnover was 145 days. Five largest suppliers represented 94% of medical-equipment purchases in 2015.
  • Debt, investment and governance: Debt service, pledged assets and restricted cash, foreign-exchange exposure, related-party financing, and the planned capital program present funding risks. A dual-class structure gives Class B shares ten votes each; the filing describes planned conversion of founder-linked shares that would confer 93.7% of voting rights.
  • Litigation: In February 2016, a subsidiary sued PLA 252 Hospital over financial disputes. The case was pending, and the company said it could not reliably estimate its likelihood of success or potential liabilities. No other material proceedings were disclosed.
  • Controls and audit: Management and the auditor reported effective internal control over financial reporting, with unqualified audit opinions. However, the control assessment and auditor’s control audit excluded the acquired Singapore hospital, which was included in the consolidated financial statements.

Important facts for investors to verify

  • Standalone quarterly results, since the filing reports annual results and does not give clear Q4 figures.
  • Whether operating cash generation, available credit lines and restricted cash can support the stated construction and expansion program without additional financing.
  • The drivers and persistence of the sharp gross-margin decline, rising operating expenses, receivable collection delays and patient-volume declines.
  • Actual construction budgets, milestones, licensing status and expected funding for the proton center and planned hospitals.
  • The Singapore hospital’s reported losses and the distinction between its reported net loss and any inconsistent narrative figures in the filing.
  • Progress and potential financial impact of the PLA 252 Hospital litigation, equipment licensing matters and unrecognized tax positions.
  • Related-party loan terms and repayment, the declared dividend’s payment status, and the impact of dual-class voting control on minority shareholders.